**Aspirin for Primary Prevention of Cardiovascular Disease in Chronic Kidney Disease: Where Do We Stand?**

Hugh Gallagher1 FRCP, PhD**,** Mark Lown2 MBBS, PhD MRCGP**,** Ahmet Fuat3 MBChB, PhD, FRCGP, FRCP London, FRCP Edinburgh PG Dip (Cardiology)**,** Paul Roderick2 MD, FRCP, FFPH.

**1** SW Thames Renal Unit, Epsom and St. Hellier NHS Trust, Renal Unit, St Helier Hospital, SM5 1AA

**2** Primary Care and Population Sciences, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, SO165ST.

**3** GP Specialist in Cardiology, Darlington Memorial Hospital. Senior Clinical Lecturer, Centre for Integrated Health Care Research, University of Durham, Stockton-on-Tees, TS17 6BH.

Address for correspondence: Hugh Gallagher, SW Thames Renal Unit, Epsom and St. Hellier NHS Trust, Renal Unit, St Helier Hospital, SM5 1AA. Email: hugh.gallagher1@nhs.net

**Introduction**

Chronic kidney disease (CKD) is defined as any abnormality of kidney function or structure with implications for health that is present for more than three months. It is classified according to the estimated glomerular filtration rate (eGFR) and urine albumin:creatinine ratio (ACR). The presence of an eGFR < 60 mL/min/1.73m2 or an ACR >= 3 mg/mmol for more than 90 days is diagnostic of CKD.

Chronic Kidney disease (CKD) is common. Using eGFR levels and urinary albumin in England (2016), 15% of adults aged 35 and over had any CKD (stage 1 to 5), and 7% had CKD stage 3 to 5 (1). An important minority of people with CKD will progress to end-stage renal disease and require renal replacement therapy, but the greatest significance of CKD is as a powerful and potentially modifiable risk factor for cardiovascular disease (CVD). Large-scale robust epidemiological data indicate that the risks of both all-cause mortality and cardiovascular (CV) mortality in the general population increase with eGFR < 60 mL/min/1.73m2 or an ACR >= 1 mg/mmol. The risks are graded: compared to eGFR 95 ml/min/1·73 m2, hazard ratios for CV mortality at eGFR 60, 45, and 15 ml/min/1·73 m2 are approximately 1.5, 2 and 3 respectively; a similar pattern is seen with rising urine ACR. eGFR and ACR are multiplicatively associated with mortality risk with no evidence of interaction (2)

The pattern of vascular events in people with CKD varies according to disease severity. In less severe renal disease atherothrombotic events dominate. With severe impairment of eGFR and in particular in those receiving renal replacement therapy, atherosclerotic events are proportionally less common and serious arrhythmia and heart failure more important.

**Aspirin and secondary prevention in the general population**

There is good evidence that antiplatelet therapy reduces the risk of subsequent vascular events in patients with pre-existing CVD (secondary prevention) and that overall the benefits outweigh the risks of major bleeding (the principal complication of therapy). A meta-analysis conducted by the Antithrombotic Trialists’ Collaboration (ATC) found a relative risk reduction of 22% in major vascular events (MVE: non-fatal myocardial infarction [MI], non-fatal stroke and cardiovascular death) in those treated with antiplatelet agents (primarily aspirin*)* compared with controls. Overall in this high-risk group (annual absolute risk of MVE greater than 3%) aspirin prevented 10-20 MVE per 1,000 patient-years (3). Aspirin is recommended internationally for the secondary prevention of cardiovascular events in people with established cardiovascular disease.

**Aspirin and primary prevention in the general population**

In lower risk populations without pre-existing CVD the benefits of aspirin for the primary prevention of CVD are smaller and largely offset by the risks of bleeding, assuming equivalence of impact of cardiovascular and bleeding events.Consequently, current guidance does not support this use of aspirin, either for the general low risk population or for those with diabetes**.**  An ATC meta-analysis of six primary prevention studies reported a 12% proportional reduction in MVE in a low risk population: the annual rate of MVE was 0.51% in aspirin-treated patients vs 0.57% in controls, with major bleeding experienced by 0.10% and 0.07% per year in the two groups respectively. Only 1-3 MVE per 1,000 patient-years were prevented (4).

Broadly similar results were seen in ASCEND, a large trial of aspirin for primary prevention of cardiovascular disease in people with diabetes published in 2018 (5). Two further primary prevention trials published the same year (ARRIVE, in people at moderate CV risk; and ASPREE in healthy older people) found no statistically significant benefits on major vascular events. However, it is noteworthy that in all three trials the baseline CV risk of the populations studied was not dissimilar to that of the aforementioned low risk historical primary prevention populations (annual rate of MVE 0.9-1.3% in control subjects), probably reflecting uptake of effective contemporary risk management strategies.

**Is there a role for aspirin primary prevention in CKD?**

Despite the existence of a substantial body of evidence, uncertainties still remain over whether and under what circumstances aspirin should be used for primary prevention. A key group in whom the balance of benefits and risk remains uncertain is those with CKD.

CKD substantially increases the risks of CV events, with a graded relationship between advancing stages of CKD and rates of fatal and non-fatal MI, and the probability of death following MI (6). In the Renal Risk in Derby Cohort (mean eGFR 52mL/min/1.73m2, 16% with albuminuria, 22% with pre-existing CVD) the annual rate of fatal and non-non-fatal CVD was 2.5% (7). The absolute benefits of aspirin may therefore be higher in the CKD population than in lower risk groups even if the relative risk reductions are similar.

It is also possible that the relative risk reductions in CVD with aspirin are greater in people with CKD than in those with normal kidney function. Some support for this contention is found in a post-hoc CKD subgroup analysis from the HOT primary prevention trial where overall, aspirin reduced the risk of major vascular events by 15%. Per 1,000 patient years aspirin prevented 1 (-1 to 2), 2 (-2 to 5) and 20 (6 to 32) major cardiovascular events for patients with baseline eGFR of ≥60, 45 to 59, and <45mL/min/1.73m2 respectively. On sensitivity analysis eGFR appeared to define the threshold for benefit (8).

However, it is unclear to what extent any benefits may be offset because people with CKD are also at increased risk of major bleeding. Many people with CKD are elderly, which is a risk factor for aspirin-associated bleeding. There are additional specific mechanisms through which the bleeding tendency is increased in CKD, including defective platelet adhesion to the sub-endothelium, defective platelet aggregation, and other intrinsic platelet defects.

A 2016 systematic review exploring the use of aspirin for primary prevention of CVD in CKD concluded that insufficient randomised control trial data exists to recommend either universal use or avoidance of aspirin for primary prevention of cardiovascular events in CKD and that the limitations of the evidence highlighted the need for definitive CKD-specific randomised controlled trials (9). Dad *et al.* concluded, in their review of 2016 US guidance on primary prevention with aspirin, that “given existing clinical equipoise, the affordability of aspirin, the wide acceptance of aspirin as potentially therapeutic by patients, and the high risk for CVD in advanced kidney disease, adequately powered clinical trials are urgently needed and should be a priority for funding agencies” (10). In 2014 the National Institute for Heath and Care Excellence recommended a definitive trial of aspirin for primary prevention of CVD in people with CKD. Whilst large trials have been published since these commentaries and recommendations, people with CKD have not been well-represented in these studies: for example, the proportion with an eGFR < 60mL/min/1.73m2 in ASCEND and ASPREE was 12% and 19% respectively.

**Conclusion**

The burden of CVD in CKD is substantial and financial impact large: assuming unit costs of £12,200 for a stroke and £7,734 for an MI and incidence of stroke and MI of 12.0 and 11.9 per 1,000 patient-years respectively in people with CKD (11), the annual costs of strokes and MI in people with CKD in England is in the order of £1bn. Although there is strong evidence for statins for primary prevention of CVD in CKD and they are recommended for all stages of CKD, our understanding of how to further reduce cardiovascular risk in CKD is limited. These limitations drive uncertainty and variation in practice. In the UK it has been estimated that there are more than 3 million people with CKD and no CVD who are not prescribed aspirin but around one million that are receiving aspirin for primary prevention in the absence of definitive evidence, potentially contributing to treatment burden (12). Pragmatic trial evidence to guide future practice in this high-risk group is urgently required.

**Word Count:** 1293

**References**

1. [Ng Fat L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ng%20Fat%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26990093), [Mindell JS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mindell%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=26990093), Roderick P. Health Survey for England 2016; Kidney and Liver Disease. December 2017.

2. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (London, England) [Internet]. 2010 Jun 12;375(9731):2073–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20483451

3. Antithrombotic Trialists’ Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ [Internet]. 2002;324(7329):71–86. Available from: http://view.ncbi.nlm.nih.gov/pubmed/11786451

4. Trialists A, Collaboration ATT. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet [Internet]. 2009;373(9678):1849–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673609605031

5. The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New Engl J Med. 2018;379:1529–39.

6. Shroff GR, Herzog CA. Acute myocardial infarction in patients with chronic kidney disease: How are the most vulnerable patients doing? Kidney Int. 2013;84(2):230–3.

7. McIntyre NJ, Shardlow A, Kohle N V., Fluck RJ, McIntyre CW, Taal MW. The Association of Markers of Mineral Bone Disease with CVEs in Early CKD. J Am Soc Nephrol. 2018;209:934.

8. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol [Internet]. 2010 Sep 14;56(12):956–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20828648

9. Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis [Internet]. 2016;251:177–82. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2016.06.013

10. Dad T, Weiner DE. Does an Aspirin a Day Keep the Doctor Away? Am J Kidney Dis. 2017;69(3):337–40.

11. Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant [Internet]. 2012 Oct;27 Suppl 3:iii73-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22815543

12. Major R, Shepherd D, Warwick G, Brunskill N. Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort. Nephron [Internet]. 2016;133(1):15–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27160883